Weatherly Asset Management L. P. Increases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Weatherly Asset Management L. P. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 591 shares of the medical research company’s stock after acquiring an additional 24 shares during the period. Weatherly Asset Management L. P.’s holdings in Thermo Fisher Scientific were worth $366,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of TMO. Lincoln National Corp boosted its position in Thermo Fisher Scientific by 6.8% in the first quarter. Lincoln National Corp now owns 7,810 shares of the medical research company’s stock worth $4,539,000 after purchasing an additional 496 shares during the last quarter. FORA Capital LLC raised its position in Thermo Fisher Scientific by 5.4% in the first quarter. FORA Capital LLC now owns 10,626 shares of the medical research company’s stock worth $6,176,000 after acquiring an additional 542 shares during the period. Salomon & Ludwin LLC grew its position in shares of Thermo Fisher Scientific by 5.6% during the 1st quarter. Salomon & Ludwin LLC now owns 1,550 shares of the medical research company’s stock valued at $901,000 after acquiring an additional 82 shares during the period. Diversified LLC increased its stake in shares of Thermo Fisher Scientific by 20.1% during the 1st quarter. Diversified LLC now owns 939 shares of the medical research company’s stock worth $546,000 after purchasing an additional 157 shares during the last quarter. Finally, Whittier Trust Co. lifted its stake in Thermo Fisher Scientific by 1.6% in the first quarter. Whittier Trust Co. now owns 85,611 shares of the medical research company’s stock valued at $49,757,000 after purchasing an additional 1,347 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Raymond James increased their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Bernstein Bank raised their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. Bank of America boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a report on Monday, September 16th. TD Cowen lifted their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Finally, Evercore ISI cut their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $557.92 on Friday. The stock has a market cap of $213.13 billion, a price-to-earnings ratio of 34.98, a P/E/G ratio of 3.61 and a beta of 0.79. The stock’s 50-day moving average is $599.39 and its 200 day moving average is $583.51. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 1-year low of $437.26 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm’s revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.69 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now owns 12,736 shares of the company’s stock, valued at $7,134,197.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,300 shares of company stock valued at $6,831,268. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.